Lupin launches Mesalamine Extended-Release Capsules 0.375 g in US market

Topics
Health Medical Pharma

Capital Market 

Lupin announced the launch of authorized generic version of Bausch Health's Apriso (Mesalamine Extended-Release Capsules 0.375 g) in the U.

S.

Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso had an annual sales of approximately USD 290 million in the U. S. (IQVIA MAT March 2020).

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, May 19 2020. 13:41 IST